Study Medication
PBI-410 is a medicine that is being tested to treat advanced solid tumors. In many cancer cells, there’s a protein called “Trop-2” that’s more abundant than in healthy cells. PBI-410 is made with an antibody that targets Trop-2 and is linked to a drug that fights cancer. These medicines are known as antibody-drug conjugates (ADC). The antibody in PBI-410 should help it stick to the Trop-2 protein on cancer cells. This lets the anti-cancer drug get inside the cancer cells and destroy them.
Administration of the Study Medication
The study has 2 Phases, a dose escalation phase and dose expansion phase. The goal of the first part of the study is to determine the safety and side effects of PBI-410 and to determine the best dose(s) to be used in the future.The goal of Phase 2 is to test if PBI-410 is effective in treating specific types of cancers.